Evidence mapPaperPMID 40796140Full record

ReviewGenetics2025

Drug screens using the nematode Caenorhabditis elegans.

Peter J Roy

Abstract readReview
In one paragraph

Review in Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. TaoChongBao: a large-scaleLife science alliance · 2026
    Article
  2. Chalcone andMolecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Peter J RoyDepartment of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.ORCID 0000-0003-2959-2276

Funding

Canada Research Chairs ProgramCIHR 133526CIHR 153024CIHR 173448CIHR 186156CIHR 68813
6 · The paper itself

Abstract

Since its inception as a model system, Caenorhabditis elegans has provided insight about the mechanism of action of drugs through genetic analyses. With the arrival of diverse drug-like small molecule libraries sometime later, the worm also became a platform for drug discovery that was previously inaccessible to academics. Here, the history of larger-scale drug screens using C. elegans is reviewed. The current approaches used to identify the targets and targeted pathways of the novel hits from these screens are also discussed. We focus on the development of small molecule tools for biological investigation, the discovery of novel candidate nematicides and anthelmintics, and touch on screens related to other areas of biology, including neurodegeneration. Finally, we draw attention to the fundamental aspects of C. elegans biology that lends itself to chemical genetic research. When combined with diverse small molecule libraries, the worm's tractability and genetic power make it an unparalleled whole-animal model system for early-stage drug discovery.

Indexed as

Caenorhabditis elegansDrug DiscoveryAnimalsAnthelminticsAntinematodal AgentsDrug Evaluation, PreclinicalSmall Molecule LibrariesAnthelminticsAntinematodal AgentsSmall Molecule LibrariesanthelminticsCaenorhabditis eleganscompoundsdrugsdrug screensgenetic suppressionnematicidesreviewsmall moleculeWormBase

Identifiers

PMID40796140
PMCPMC12406009

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.